Safety of Technique and Procedure of Stromal Vascular Fraction Therapy: From Liposuction to Cell Administration

Table 1

Distribution of patients’ conditions (age, gender), median of fat tissue processed, SVF processing method, repetition of treatment, and cell dose for IV injection based on pathological condition.

Group of disease	Pathological condition	Number of patients				Median of age, min and max (year)	Median of fat tissue volume, min and max (cc)	Number of patients						Median of total cell dose, min and max (billion) for IV
								SVF processing method			Repetition of treatment
		N	%	M	F			1	2	3	1	2	3	1	2	3
Diabetes mellitus	DM type 1 and 2	140	33.25	93	47	56 (13–85)	145 (20–393)	20	4	116	33	38	69	2.42 (0.003–19.24)	1.00 (0.03–8.48)	0.72 (0.13–2.92)
Antiaging	Systemic rejuvenation	72	17.10	19	53	51 (34–84)	130 (15–613)	9	1	62	22	18	32	2.08 (0.20–11.80)	1.02 (0.10–8.12)	0.62 (0.18–2.08)
Degenerative musculoskeletal disease	Osteoarthritis, osteoporosis, and herniated nucleus pulposus	47	11.16	14	33	64 (10–86)	183 (50–445)	11	1	35	13	11	23	1.11 (0.001–10.12)	0.92 (0.15–9.64)	0.44 (0.10–2.40)
Cardiovascular and metabolic disease	Cardiomyopathy, hypertension, postcardiac stenting	26	6.18	19	7	57 (4–71)	181 (45–445)	7	0	19	8	10	8	2.00 (0.04–8.18)	0.97 (0.11–5.07)	0.88 (0.21–2.10)
Autism	Autism	25	5.94	18	7	10 (5–34)	108 (30–326)	11	0	14	12	5	8	2.04 (0.001–4.24)	1.57 (0.33–3.92)	0.95 (0.13–1.64)
Autoimmune disease	Multiple sclerosis, myasthenia gravis, psoriasis, and vasculitis	24	5.70	6	18	41 (16–69)	101 (30–323)	6	0	18	6	5	13	2.30 (0.02–7.25)	1.12 (0.08–2.96)	0.69 (0.32–3.04)
Stroke	Chronic ischemic stroke	22	5.23	14	8	57 (32–75)	120 (40–399)	2	0	20	4	5	13	1.47 (0.40–19.60)	0.82 (0.08–2.64)	0.63 (0.10–2.65)
Brain disorder/brain damage	Epilepsy, cerebral palsy, postmeningitis related brain injury, posttraumatic brain damage, post-choriocarcinoma	21	4.99	16	5	12 (1–44)	65 (15–375)	4	0	17	7	7	7	1.52 (0.04–26.12)	1.20 (0.20–3.82)	0.59 (0.14–1.08)
Respiratory disease	COPD	13	3.09	10	3	68 (48–78)	230 (58–349)	7	0	6	7	2	4	1.39 (0.002–8.82)	1.77 (0.60–5.84)	0.61 (0.40–1.28)
Renal failure	Chronic renal failure	8	1.90	5	3	67 (45–76)	209 (93–305)	3	0	5	3	1	4	1.74 (1.16–4.17)	1.73 (1.20–3.94)	0.76 (0.51–1.39)
Degenerative brain disease	Parkinson’s, dementia, Alzheimer	8	1.90	6	2	61 (55–77)	98 (60–200)	0	3	5	3	0	5	1.22 (0.24–2.68)	0.28 (0.22–0.83)	0.49 (0.13–1.03)
Eye disease	Macular degeneration, retinitis pigmentosa	5	1.19	3	2	71 (49–77)	120 (80–200)	2	0	3	2	1	2	1.04 (0.14–3.05)	0.44 (0.33–0.82)	0.66 (0.31–1.01)
Neurological disorder	Mental retardation, hypoconcentration	3	0.71	1	2	27 (21–55)	60 (37–120)	0	0	3	2	0	1	1.96 (0.31–2.24)	0.16	0.10
Reproductive system target	Improving quality of sperm, climacteric	3	0.71	1	2	62 (35–62)	120 (100–285)	0	0	3	0	1	2	1.64 (1.43–2.13)	1.32 (0.45–2.76)	0.63 (0.55–0.71)
Posttrauma injury	Multiple fracture, urethrae rupture, and skin loss after trauma	2	0.48	1	1	43 (17–69)	121 (120–121)	0	0	2	1	0	1	4.81 (1.44–8.18)	0.44	0.48
Hearing problem	Deafness and hearing loss	2	0.48	1	1	36 (22–50)	179 (130–228)	0	0	2	0	1	1	3.80 (2.31–5.29)	1.90 (1.16–2.64)	0.77
Total		421	100	194	227			82	9	330	123	105	193

Method 1: SVF was isolated from lipoaspirate by commercial kit. Method 2: available method provided by stem cell laboratory in Jakarta. Method 3: H-Remedy established by HayandraLab.